Cited by 1,217Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchCholinesterase and Neurodegenerative Diseases

The DOI matches its Crossref record; 159 of the 161 references it cites were found in a registry or an index.

Alzheimer’s disease: Clinical trials and drug development

Mangialasche, Francesca, Solomon, Alina, Winblad, Bengt, Mecocci, Patrizia, Kivipelto, Miia·2010·The Lancet Neurology

DOI 10.1016/s1474-4422(10)70119-8

Open this paper in CoChat — free account

Abstract

Alzheimer's disease is the most common cause of dementia in elderly people. Research into Alzheimer's disease therapy has been at least partly successful in terms of developing symptomatic treatments, but has also had several failures in terms of developing disease-modifying therapies. These successes and failures have led to debate about the potential deficiencies in our understanding of the pathogenesis of Alzheimer's disease and potential pitfalls in diagnosis, choice of therapeutic targets, development of drug candidates, and design of clinical trials. Many clinical and experimental studies are ongoing, but we need to acknowledge that a single cure for Alzheimer's disease is unlikely to be found and that the approach to drug development for this disorder needs to be reconsidered. Preclinical research is constantly providing us with new information on pieces of the complex Alzheimer's disease puzzle, and an analysis of this information might reveal patterns of pharmacological interactions instead of single potential drug targets. Several promising randomised controlled trials are ongoing, and the increased collaboration between pharmaceutical companies, basic researchers, and clinical researchers has the potential to bring us closer to developing an optimum pharmaceutical approach for the treatment of Alzheimer's disease.

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(10)70119-8

Cites

159 of 159 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
Alzheimer’s disease
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Mortality in Randomized Trials of Antioxidant Supplements for Primary and Secondary Prevention: Systematic Review and Meta-analysis
Bjelakovic, G., Nikolova, D., Gluud, L. L., Simonetti, R. G., & Gluud, C. (2007) · JAMA · doi:10.1001/jama.297.8.842 · Cited by 2,275
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers
Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., & Strittmatter, S. M. (2009) · Nature · doi:10.1038/nature07761 · Cited by 1,560

Show all 161 references

Research works printed but not linked: 3

Solomon, 2010, A new target for Alzheimer's disease immunotherapy. 11th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2010, Geneva, Switzerland, Neurobiol Aging, 31, S29
Lenz R, Berry SM, Pritchett YL, et al. Novel investigation of a neuronal nicotinic receptor partial agonist in the treatment of Alzheimer's disease. 11th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy; Geneva, Switzerland; March 24–27, 2010. P100.
Eriksdotter, 2010, Therapy of Alzheimer's disease with NGF. 11th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2010, Geneva, Switzerland, Neurobiol Aging, 31, S9

Sorted by citations

Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics
Karran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188
ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease
Simpson, D. S. A., & Oliver, P. L. (2020) · Antioxidants · doi:10.3390/antiox9080743 · Cited by 1,044
Brain atrophy in Alzheimer’s Disease and aging
Pini, L., Pievani, M., Bocchetta, M., Altomare, D., Bosco, P., Cavedo, E., Galluzzi, S., Marizzoni, M., & Frisoni, G. B. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.002 · Cited by 836
A systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain
Wang, J., Gu, B. J., Masters, C. L., & Wang, Y.-J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.111 · Cited by 808
APP mouse models for Alzheimer’s disease preclinical studies.
Sasaguri, H., Nilsson, P., Hashimoto, S., Nagata, K., Saito, T., De Strooper, B., Hardy, J., Vassar, R., Winblad, B., & Saido, T. C. (2017) · The EMBO Journal · doi:10.15252/embj.201797397 · Cited by 793
Self-citation
BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases
Lu, B., Nagappan, G., Guan, X.-M., Nathan, P. J., & Wren, P. B. (2013) · Nature reviews. Neuroscience · doi:10.1038/nrn3505 · Cited by 763
Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer’s Disease, Parkinson’s Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis
Nguyen, P. H., Ramamoorthy, A., Sahoo, B. R., Zheng, J., Faller, P., Straub, J. E., Domínguez, L., Shea, J., Dokholyan, N. V., Simone, A. D., et al. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01122 · Cited by 680
Clinical trials and late‐stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014
Schneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12191 · Cited by 651
Self-citation
The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER): Study design and progress
Kivipelto, M., Solomon, A., Ahtiluoto, S., Ngandu, T., Lehtisalo, J., Antikainen, R., Bäckman, L., Hänninen, T., Jula, A., Laatikainen, T., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.09.012 · Cited by 589
Self-citation
Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease
Barage, S. H., & Sonawane, K. D. (2015) · Neuropeptides · doi:10.1016/j.npep.2015.06.008 · Cited by 579
Bidirectional relationship between sleep and Alzheimer’s disease: role of amyloid, tau, and other factors
Wang, C., & Holtzman, D. M. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0478-5 · Cited by 615
Energy metabolism and inflammation in brain aging and Alzheimer’s disease
Yin, F., Sancheti, H., Patil, I., & Cadenas, E. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.04.200 · Cited by 538
Screening out irrelevant cell-based models of disease
Horvath, P., Aulner, N., Bickle, M., Davies, A. M., Nery, E. D., Ebner, D., Montoya, M. C., Östling, P., Pietiäinen, V., Price, L. S., et al. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.175 · Cited by 525
Current Developments of Coumarin Compounds in Medicinal Chemistry
Peng, X.-M., Damu, G. L. V., & Zhou, C. H. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319210013 · Cited by 507
Scanning ultrasound removes amyloid-β and restores memory in an Alzheimer’s disease mouse model
Leinenga, G., & Götz, J. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa2512 · Cited by 498
The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy
McGeer, P. L., & McGeer, E. G. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1177-7 · Cited by 467
Deep learning to detect Alzheimer's disease from neuroimaging: A systematic literature review
Ghahnavieh, A. E., Luo, S., & Chiong, R. (2019) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2019.105242 · Cited by 456
Artificial intelligence and machine learning-aided drug discovery in central nervous system diseases: State-of-the-arts and future directions
Vatansever, S., Schlessinger, A., Wacker, D., Kaniskan, H. Ü., Jin, J., Zhou, M., & Zhang, B. (2021) · Medicinal Research Reviews · doi:10.1002/med.21764 · Cited by 429
Cognitive function in patients with diabetes mellitus: guidance for daily care
Koekkoek, P. S., Kappelle, L. J., van den Berg, E., Rutten, G. E. H. M., & Biessels, G. J. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70249-2 · Cited by 422
Recent advances in siRNA delivery mediated by lipid-based nanoparticles
Yonezawa, S., Koide, H., & Asai, T. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.022 · Cited by 394
Alzheimer's Disease and the Amyloid Cascade Hypothesis: A Critical Review
Reitz, C. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/369808 · Cited by 398
Microglia in the Neuroinflammatory Pathogenesis of Alzheimer’s Disease and Related Therapeutic Targets
Cai, Y., Liu, J., Wang, B., Sun, M., & Yang, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.856376 · Cited by 351
Comprehensive review of mechanisms of pathogenesis involved in Alzheimer’s disease and potential therapeutic strategies
Sharma, P., Srivastava, P., Seth, A., Tripathi, P. N., Banerjee, A. G., & Shrivastava, S. K. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.006 · Cited by 331
New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs
Salomone, S., Caraci, F., Leggio, G. M., Fedotova, J., & Drago, F. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04134.x · Cited by 335
Recent Advances in the Inhibition of p38 MAPK as a Potential Strategy for the Treatment of Alzheimer’s Disease
Lee, J. K., & Kim, N. (2017) · Molecules · doi:10.3390/molecules22081287 · Cited by 326
Mouse models of Alzheimer's disease
Hall, A. M., & Roberson, E. D. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.11.017 · Cited by 317
Tonic inhibition in dentate gyrus impairs long-term potentiation and memory in an Alzheimer’s disease model
Wu, Z., Guo, Z., Gearing, M., & Chen, G. (2014) · Nature Communications · doi:10.1038/ncomms5159 · Cited by 306
Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends
Бачурин, С. О., Bovina, E. V., & Ustyugov, A. A. (2017) · Medicinal Research Reviews · doi:10.1002/med.21434 · Cited by 317
Drug repositioning for Alzheimer's disease
Corbett, A., Pickett, J., Burns, A. S., Corcoran, J. P. T., Dunnett, S. B., Edison, P., Hagan, J. J., Holmes, C., Jones, E., Katona, C., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3869 · Cited by 307
Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions
Andrieu, S., Coley, N., Lovestone, S., Aisen, P. S., & Vellas, B. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00153-2 · Cited by 293
Exercise counteracts declining hippocampal function in aging and Alzheimer's disease
Intlekofer, K. A., & Cotman, C. W. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.06.011 · Cited by 300
Neuroprotective and Anti-Aging Potentials of Essential Oils from Aromatic and Medicinal Plants
Ayaz, M., Sadiq, A., Junaid, M., Ullah, F., Subhan, F., & Ahmed, J. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00168 · Cited by 297
A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease
Karran, E. H., & Hardy, J. (2014) · Annals of Neurology · doi:10.1002/ana.24188 · Cited by 279
Novel advances in shotgun lipidomics for biology and medicine
Wang, M., Wang, C., Han, R. H., & Han, X. (2015) · Progress in Lipid Research · doi:10.1016/j.plipres.2015.12.002 · Cited by 274
Bioactive metabolites from macrofungi: ethnopharmacology, biological activities and chemistry
Silva, D. D. D., Rapior, S., Sudarman, E., Stadler, M., Xu, J., Alias, S. A., & Hyde, K. D. (2013) · Fungal Diversity · doi:10.1007/s13225-013-0265-2 · Cited by 269
Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease
Mecocci, P., & Polidori, M. C. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.10.006 · Cited by 277
Self-citation
Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond
Song, C., Shi, J., Zhang, P., Zhang, Y., Xu, J., Zhao, L., Zhang, R., Wang, H., & Chen, H. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00292-3 · Cited by 266
Tau-aggregation inhibitor therapy for Alzheimer's disease
Wischik, C. M., Harrington, C. R., & Storey, J. M. D. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.008 · Cited by 279
Frames and counter-frames giving meaning to dementia: A framing analysis of media content
Gorp, B. V., & Vercruysse, T. (2012) · Social Science & Medicine · doi:10.1016/j.socscimed.2011.12.045 · Cited by 253
Rodent models of neuroinflammation for Alzheimer’s disease
Nazem, A., Sankowski, R., Bacher, M., & Al‐Abed, Y. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0291-y · Cited by 258
First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model
Kontseková, E., Žilka, N., Kováčech, B., Novák, P., & Novák, M. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt278 · Cited by 266
Nrf2: a dark horse in Alzheimer's disease treatment
Osama, A., Zhang, J., Yao, J., Yao, X., & Fang, J. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101206 · Cited by 264
In Vitro Screening for Anti-Cholinesterase and Antioxidant Activity of Methanolic Extracts of Ayurvedic Medicinal Plants Used for Cognitive Disorders
Mathew, M., & Subramanian, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086804 · Cited by 237
Transcriptional data: a new gateway to drug repositioning?
Iorio, F., Rittman, T., Ge, H., Menden, M. P., & Sáez-Rodríguez, J. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.07.014 · Cited by 246
Current and Emerging Drug Treatment Options for Alzheimerʼs Disease
Herrmann, N., Chau, S. A., Kircanski, I., & Lanctôt, K. L. (2011) · Drugs · doi:10.2165/11595870-000000000-00000 · Cited by 245
The future of Alzheimer's disease: The next 10 years
Hampel, H. J., Prvulovic, D., Teipel, S. J., Jessen, F., Luckhaus, C., Frölich, L., Riepe, M. W., Dodel, R. C., Leyhe, T., Bertram, L., et al. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.11.008 · Cited by 238
Multivariate Data Analysis and Machine Learning in Alzheimer's Disease with a Focus on Structural Magnetic Resonance Imaging
Falahati, F., Westman, E., & Simmons, A. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131928 · Cited by 241
In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer's Disease
Watt, G., & Karl, T. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00020 · Cited by 237
Nanotechnology-based drug delivery systems for Alzheimer's disease management: Technical, industrial, and clinical challenges
Wen, M. M., El-Salamouni, N. S., El-Refaie, W. M., Hazzah, H. A., Ali, M. M., Tosi, G., Farid, R. M., Blanco‐Prieto, M. J., Billa, N., & Hanafy, A. S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.025 · Cited by 228
Modulation of neurotrophic signaling pathways by polyphenols
Firuzi, O., Moosavi, F., Hosseini, R., & Saso, L. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s96936 · Cited by 230
Chemical Kinetics for Bridging Molecular Mechanisms and Macroscopic Measurements of Amyloid Fibril Formation
Michaels, T. C. T., Šarić, A., Habchi, J., Chia, S., Meisl, G., Vendruscolo, M., Dobson, C. M., & Knowles, T. P. J. (2018) · Annual Review of Physical Chemistry · doi:10.1146/annurev-physchem-050317-021322 · Cited by 222
Anti-Alzheimer’s Studies on β-Sitosterol Isolated from Polygonum hydropiper L.
Ayaz, M., Junaid, M., Ullah, F., Subhan, F., Sadiq, A., Ali, G., Ovais, M., Shahid, M., Ahmad, A., Wadood, A., et al. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00697 · Cited by 220
Early-Onset Familial Alzheimer's Disease (EOFAD)
Wu, L., Rosa‐Neto, P., Hsiung, G. R., Sadovnick, A. D., Masellis, M., Black, S. E., Jia, J., & Gauthier, S. G. (2012) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100013949 · Cited by 240
Alkaloids as a source of potential anticholinesterase inhibitors for the treatment of Alzheimer's disease
Konrath, E. L., Passos, C. D. S., Klein‐Júnior, L. C., & Henriques, A. T. (2013) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12090 · Cited by 223
Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer’s disease
Park, J.-H., Ju, Y. H., Choi, J. W., Song, H. J., Jang, B. K., Woo, J., Chun, H., Kim, H. J., Shin, S. J., Yarishkin, O., et al. (2019) · Science Advances · doi:10.1126/sciadv.aav0316 · Cited by 216
Causal machine learning for healthcare and precision medicine
Sanchez, P., Voisey, J. P., Xia, T., Watson, H. I., O’Neil, A. Q., & Tsaftaris, S. A. (2022) · Royal Society Open Science · doi:10.1098/rsos.220638 · Cited by 243
The main cost drivers in dementia: a systematic review: Systematic review of COI studies in dementia focusing on care settings
Schaller, S., Mauskopf, J., Kriza, C., Wahlster, P., & Kolominsky-Rabas, P. L. (2015) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4198 · Cited by 215
Alzheimer's therapeutics: Continued clinical failures question the validity of the amyloid hypothesis—but what lies beyond?
Mullane, K., & Williams, M. J. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.11.014 · Cited by 219
Mitochondrial Dysfunction: a Potential Therapeutic Target to Treat Alzheimer’s Disease
Nand, S., Singh, C., Singh, A., Singh, M. P., & Singh, S. P. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01945-y · Cited by 215
Regulation of Copper and Iron Homeostasis by Metal Chelators: A Possible Chemotherapy for Alzheimer’s Disease
Robert, A., Liu, Y., Nguyen, M., & Meunier, B. (2015) · Accounts of Chemical Research · doi:10.1021/acs.accounts.5b00119 · Cited by 212
Noncoding RNAs in Alzheimer's disease
Idda, M. L., Munk, R. B., Abdelmohsen, K., & Gorospe, M. (2018) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1463 · Cited by 211
Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project
Ritchie, C. W., Molinuevo, J. L., Truyen, L., Satlin, A., der Geyten, S. V., & Lovestone, S. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00454-x · Cited by 202
Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer’s Disease
Agis-Torres, A., Sollhuber, M., Fernandez, M., & Sanchez-Montero, J. M. (2014) · Current Neuropharmacology · doi:10.2174/1570159x113116660047 · Cited by 202
Current treatment options for Alzheimer’s disease and Parkinson’s disease dementia
Y.Y. Szeto, J., & J.G. Lewis, S. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666151208112754 · Cited by 198
Network Dysfunction in Alzheimer's Disease: Refining the Disconnection Hypothesis
Brier, M. R., Thomas, J., & Ances, B. M. (2014) · Brain Connectivity · doi:10.1089/brain.2014.0236 · Cited by 203
Life Extension Factor Klotho Prevents Mortality and Enhances Cognition in hAPP Transgenic Mice
Dubal, D. B., Zhu, L., Sanchez, P. E., Worden, K., Broestl, L., Johnson, E. C. B., Ho, K., Yu, G.-Q., Kim, D., Bétourné, A., et al. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.5791-12.2015 · Cited by 196
Mild Cognitive Impairment: Diagnosis, Longitudinal Course, and Emerging Treatments
Vega, J. N., & NEWHOUSE, P. A. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0490-8 · Cited by 211
Inhibition of AMP-activated protein kinase signaling alleviates impairments in hippocampal synaptic plasticity induced by amyloid β
Ma, T., Chen, Y., Vingtdeux, V., Zhao, H., Viollet, B., Marambaud, P., & Klann, E. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.1694-14.2014 · Cited by 191
Epidermal growth factor receptor is a preferred target for treating Amyloid-β–induced memory loss
Wang, L., Chiang, H.-C., Wu, W., Liang, B., Xie, Z., Yao, X., Ma, W., Du, S., & Zhong, Y. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208011109 · Cited by 190
Biomaterial Scaffold Fabrication Techniques for Potential Tissue Engineering Applications
Subia, B., Kundu, S. C., & C., S. (2010) · InTech eBooks · doi:10.5772/8581 · Cited by 193
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial
Dodel, R. C., Rominger, A., Bartenstein, P., Barkhof, F., Blennow, K., Förster, S., Winter, Y., Bach, J., Popp, J., Alferink, J., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70014-0 · Cited by 193
Understanding the Amyloid Hypothesis in Alzheimer’s Disease
Paroni, G., Bisceglia, P., & Seripa, D. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180802 · Cited by 194
Oxidative Damage to RNA in Aging and Neurodegenerative Disorders
Nunomura, A., Moreira, P. I., Castellani, R. J., Lee, H., Zhu, X., Smith, M. A., & Perry, G. L. (2012) · Neurotoxicity Research · doi:10.1007/s12640-012-9331-x · Cited by 185
Neuroinflammation in Alzheimer’s disease; A source of heterogeneity and target for personalized therapy
Latta, C. H., Brothers, H. M., & Wilcock, D. M. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.09.061 · Cited by 188
Anti-Aβ Drug Screening Platform Using Human iPS Cell-Derived Neurons for the Treatment of Alzheimer's Disease
Yahata, N., Asai, M., Kitaoka, S., Takahashi, K., Asaka, I., Hioki, H., Kaneko, T., Maruyama, K., Saido, T. C., Nakahata, T., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025788 · Cited by 177
A brief overview of amyloids and Alzheimer's disease
Ow, S., & Dunstan, D. E. (2014) · Protein Science · doi:10.1002/pro.2524 · Cited by 188
Multi-Target Directed Drugs: A Modern Approach for Design of New Drugs for the treatment of Alzheimer’s Disease
Dias, K. S. T., & Viegas, C. (2014) · Current Neuropharmacology · doi:10.2174/1570159x1203140511153200 · Cited by 178
Cathepsin B in neurodegeneration of Alzheimer's disease, traumatic brain injury, and related brain disorders
HOOK, V. Y. H., Yoon, M. C., Mosier, C., Ito, G., Podvin, S., Head, B. P., Rissman, R. A., O’Donoghue, A. J., & Hook, G. (2020) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2020.140428 · Cited by 177
Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer’s disease: A network meta-analysis of 41 randomized controlled trials
Dou, K.-X., Tan, M.-S., Tan, C.-C., Cao, X.-P., Hou, X.-H., Guo, Q.-H., Tan, L., Mok, V., & Yu, J.-T. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0457-9 · Cited by 171
Secretase inhibitors for the treatment of Alzheimer's disease: Long road ahead
Kumar, D., Ganeshpurkar, A., Kumar, D., Modi, G. P., Gupta, S., & Singh, S. K. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.02.035 · Cited by 170
Human neural stem cells alleviate Alzheimer-like pathology in a mouse model
Lee, I.-S., Jung, K., Kim, I., Lee, H.-J., Kim, M., Yun, S., Hwang, K., Shin, J. E., & Park, K. I. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0035-6 · Cited by 170
Microenvironment Remodeling Micelles for Alzheimer's Disease Therapy by Early Modulation of Activated Microglia
Lü, Y., Guo, Z., Zhang, Y., Li, C., Zhang, Y., Guo, Q., Chen, Q., Chen, X., He, X., Liu, L., et al. (2018) · Advanced Science · doi:10.1002/advs.201801586 · Cited by 164
Therapeutic approaches to Huntington disease: from the bench to the clinic
Caron, N. S., Dorsey, E. R., & Hayden, M. R. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.133 · Cited by 168
Neuroprotective Role of Phytochemicals
Velmurugan, B. K., Baskaran, R., Lohanathan, B. P., Thiyagarajan, V., & Weng, C. (2018) · Molecules · doi:10.3390/molecules23102485 · Cited by 163
Serotonin 5-HT6Receptor Antagonists for the Treatment of Cognitive Deficiency in Alzheimer’s Disease
Benhamú, B., Martín‐Fontecha, M., Vázquez‐Villa, H., Pardo, L., & López-Rodríguez, M. L. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5003952 · Cited by 160
Design of LVFFARK and LVFFARK-Functionalized Nanoparticles for Inhibiting Amyloid β-Protein Fibrillation and Cytotoxicity
Xiong, N., Dong, X., Zheng, J., Liu, F., & Sun, Y. P. (2015) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5b00915 · Cited by 160
Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases
Lleó, A., Cavedo, E., Parnetti, L., Vanderstichele, H., Herukka, S., Andreasen, N., Ghidoni, R., Lewczuk, P., Jeromin, A., Winblad, B. G., et al. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.232 · Cited by 162
Self-citation
MicroRNAs in Alzheimer's disease: Potential diagnostic markers and therapeutic targets
Liu, S., Fan, M., Zheng, Q., Hao, S., Yang, L., Xia, Q., Qi, C., & Ge, J. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112681 · Cited by 158
Amyloid‐ß‐directed immunotherapy for Alzheimer's disease
Lannfelt, L., Relkin, N. R., & Siemers, E. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12168 · Cited by 161
Alzheimer's disease, enzyme targets and drug discovery struggles: From natural products to drug prototypes
Silva, T., Reis, J., Teixeira, J., & Borges, F. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.03.008 · Cited by 158
The Important Role of Zinc in Neurological Diseases
Li, Z., Liu, Y., Wei, R., Yong, V. W., & Xue, M. (2022) · Biomolecules · doi:10.3390/biom13010028 · Cited by 170
Targeting drugs to mitochondria
Heller, A., Brockhoff, G., & Göpferich, A. M. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.05.014 · Cited by 156
Effects of Home Photobiomodulation Treatments on Cognitive and Behavioral Function, Cerebral Perfusion, and Resting-State Functional Connectivity in Patients with Dementia: A Pilot Trial
Chao, L. L. (2019) · Photobiomodulation Photomedicine and Laser Surgery · doi:10.1089/photob.2018.4555 · Cited by 155
From mild cognitive impairment to subjective cognitive decline: conceptual and methodological evolution.
Cheng, Y.-W., Chen, T.-F., & Chiu, M.-J. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s123428 · Cited by 150
Targeting of XJB-5-131 to Mitochondria Suppresses Oxidative DNA Damage and Motor Decline in a Mouse Model of Huntington’s Disease
Xun, Z., Rivera, S., Ayala‐Peña, S., Lim, J. I., Budworth, H., Skoda, E. M., Robbins, P. D., Niedernhofer, L. J., Wipf, P., & McMurray, C. T. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.10.001 · Cited by 155
Clinical Utility and Analytical Challenges in Measurement of Cerebrospinal Fluid Amyloid-β1–42 and τ Proteins as Alzheimer Disease Biomarkers
Kang, J., Korecka, M., Toledo, J. B., Trojanowski, J. Q., & Shaw, L. M. J. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2013.202937 · Cited by 147
Biomarkers in Alzheimer's disease drug development
Blennow, K. (2010) · Nature Medicine · doi:10.1038/nm.2221 · Cited by 145
Inadequate supply of vitamins and DHA in the elderly: Implications for brain aging and Alzheimer-type dementia
Mohajeri, M. H., Troesch, B., & Weber, P. (2015) · Nutrition · doi:10.1016/j.nut.2014.06.016 · Cited by 141
Current and emerging avenues for Alzheimer's disease drug targets
Loera‐Valencia, R., Cedazo-Mínguez, Á., Kenigsberg, P.-A., Page, G., Duarte, A. I., Giusti, P., Zusso, M., Robert, P. H., Frisoni, G. B., Cattaneo, A., et al. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12959 · Cited by 142
Self-citation

Authors: Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M.
Affiliations: University of Perugia (IT)
University of Eastern Finland (FI)
Karolinska Institutet (SE)
Corresponding author: Winblad, Bengt
ORCID: Mangialasche, Francesca
Solomon, Alina
Winblad, Bengt
Mecocci, Patrizia
Kivipelto, Miia
Venue: The Lancet Neurology
Publisher: Elsevier BV
Published: 2010-07
Volume: 9
Issue: 7
Pages: 702-716
ISSN: 1474-4422 (ISSN-L)
DOI: 10.1016/s1474-4422(10)70119-8
OpenAlex: W2129267808
Cited by: 1,217
References: 161
Citations by year: 2026: 31 · 2025: 47 · 2024: 53 · 2023: 45 · 2022: 91 · 2021: 80 · 2020: 69 · 2019: 77 · 2018: 82 · 2017: 79 · 2016: 78 · 2015: 89 · 2014: 121 · 2013: 97 · 2012: 80
FWCI: 8.96
Type: journal article
Language: en
Update notices: erratum (2011-06-01)
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet Neurology (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords: Alzheimer's disease, drug development, clinical trials, disease-modifying therapy, symptomatic treatment, therapeutic target, pathogenesis, dementia, drug interactions, randomized controlled trials, translational research
MeSH terms: Alzheimer Disease, Clinical Trials as Topic, Humans, Antipsychotic Agents, Drug Design

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Alzheimer’s disease: Clinical trials and drug development

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks